Source-grounded facts extracted from Akari Therapeutics Plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Akari Therapeutics Plc entered into Purchase Agreement with certain investors valued at approximately $5.5 million (effective 2026-05-20).
“On May 20, 2026, Akari Therapeutics, Plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain investors”
Akari Therapeutics Plc issued common stock.
“On March 17, 2026, Akari Therapeutics, Plc (the “Company”) announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) evidencing ordinary shares, par value 0.000000005 per share (“Ordinary Shares”), from one (1) ADS representing two thousand (2,000) Ordinary Share to one (1) ADS representing eighty thousand (80,000) Ordinary Shares (the “Ratio Change”).”
Akari Therapeutics Plc entered into Placement Agent Agreement with Ladenburg Thalmann & Co. Inc. (effective 2025-12-16).
“The Company also entered into a placement agency agreement (the “Placement Agent Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”), pursuant to which the Placement Agent agreed to serve as the exclusive placement agent for the Company in connection with the Offering.”
Akari Therapeutics Plc entered into PIPE Purchase Agreement with certain directors and officers of the Company valued at approximately $5 million (effective 2025-12-16).
“In a concurrent Private Placement, pursuant to a securities purchase agreement dated as of December 16, 2025 (the “PIPE Purchase Agreement”, and, together with the RDO Purchase Agreement, the “Purchase Agreements”), the Company agreed to issue to certain directors and officers of the Company (i) unregistered pre-funded warrants (“Pre-Funded Warrants”, and, together with the Series G Warrants, the “Warrants”) to purchase an aggregate of 2,563,713 ADSs at an exercise price per ADS of $0.00001, and (ii) accompanying Series G Warrants to purchase an aggregate of 2,563,713 ADSs, at a combined purchase price of $0.4041 per Pre-Funded Warrant and Series G Warrant.”
Akari Therapeutics Plc entered into RDO Purchase Agreement with certain institutional investors valued at approximately $5 million (effective 2025-12-16).
“On December 16, 2025, Akari Therapeutics, Plc (the “Company”) entered into a securities purchase agreement (the “RDO Purchase Agreement”) with certain institutional investors providing for the issuance and sale, in the Registered Direct Offering, of 10,043,774 American Depositary Shares (“ADSs”), each representing 2,000 ordinary shares, par value $0.000000005 per share (“Ordinary Shares”), of the Company.”
Akari Therapeutics Plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“November 24, 2025, Akari Therapeutics, Plc (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive busines”
Akari Therapeutics Plc issued Placement Agent warrants to purchase up to 125,000 ADSs of warrant to Placement Agent for Issued as compensation for placement agent services; exercise price $1.00 per share; 5-year term.
“The Placement Agent or its designees will also receive warrants (the “Placement Agent Warrants”) on substantially the same terms as the Series E Warrants in an amount equal to 4.0% of the aggregate number of ADSs sold in the Offering, or Placement Agent warrants to purchase up to 125,000 ADSs, at an exercise price of $1.00 per share and will have a 5-year term from the commencement of sales of the Offering.”
Akari Therapeutics Plc issued Series E warrants to purchase up to 3,125,000 ADSs and Series F warrants to purchase up to 3,125,000 ADSs of warrant to institutional investors for Issued as part of unit with ADS at $0.80 per combined unit; exercise price $0.98 per share.
“E Warrants, the “Warrants”), which are being issued in a concurrent private placement. The combined purchase price per each ADS and accompanying Warrants sold in the Offering is $0.80. The aggregate gross proceeds from the Offering are expected to be approximately $2.5 million, excluding any proceeds from any future exercises of Warrants. The Offering”
Akari Therapeutics Plc issued 3,125,000 ADSs each representing 2,000 ordinary shares of unit to institutional investors for $0.80 per combined ADS and accompanying warrants, aggregate gross proceeds approximately $2.5 million.
“E Warrants, the “Warrants”), which are being issued in a concurrent private placement. The combined purchase price per each ADS and accompanying Warrants sold in the Offering is $0.80. The aggregate gross proceeds from the Offering are expected to be approximately $2.5 million, excluding any proceeds from any future exercises of Warrants. The Offering”
Akari Therapeutics Plc incurred debt of $2,826,250 maturing 12-month anniversary of the respective Closing Dates.
“the Company completed its first tranche of closings of the Offering and issued Notes with an aggregate purchase price of $2,261,000 and an aggregate principal amount of $2,826,250”
Akari Therapeutics Plc completed an acquisition involving Peak Bio, Inc. (closed 2024-11-14).
“On November 14, 2024, Akari completed the previously announced strategic combination (the "Closing") contemplated by that Agreement and Plan of Merger by and among Akari, Peak Bio, Inc. ("Peak Bio") and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Akari ("Merger Sub") as amended by that certain side letter dated August 15, 2024 (the "Merger Agreement"), pursuant to which, upon the terms and subject to the conditions thereof, Merger Sub was merged with and into Peak Bio (the "Merger"), with Peak Bio surviving the Merger as a wholly owned subsidiary of Akari.”
Sandip Patel was appointed as Director at Akari Therapeutics Plc.
“As previously disclosed, effective as of the Effective Time and pursuant to the terms of the Merger Agreement, the Akari Board appointed Hoyoung Huh, M.D., Ph. D, James Neal and Sandip Patel, each of whom were members of the board of directors of Peak Bio, to serve as directors for a term commencing upon the Effective Time.”
James Neal was appointed as Director at Akari Therapeutics Plc.
“As previously disclosed, effective as of the Effective Time and pursuant to the terms of the Merger Agreement, the Akari Board appointed Hoyoung Huh, M.D., Ph. D, James Neal and Sandip Patel, each of whom were members of the board of directors of Peak Bio, to serve as directors for a term commencing upon the Effective Time.”
Hoyoung Huh was appointed as non-executive chairman at Akari Therapeutics Plc.
“Dr. Huh will serve as the non-executive chairman of the Akari Board as of the Effective Time.”
Donald Williams resigned as Director at Akari Therapeutics Plc.
“Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.”
Wa'el Hashad resigned as Director at Akari Therapeutics Plc.
“Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.”
Robert Bazemore was appointed as director at Akari Therapeutics Plc.
“the appointment of Robert Bazemore to serve as a director of the Board, effective as of September 17, 2024”
Rachelle Jacques departed as President and Chief Executive Officer at Akari Therapeutics Plc.
“Rachelle Jacques stepped down as the President and Chief Executive Officer of the Company, effective May 1, 2024”
Samir R. Patel was appointed as Interim President and Chief Executive Officer at Akari Therapeutics Plc.
“As previously disclosed, on April 25, 2024, the board of directors (the “Board”) of Akari Therapeutics, Plc (the “Company”) appointed Samir R. Patel, M.D., a member of the Board, as Interim President and Chief Executive Officer, effective May 1, 2024, to serve in such capacities until such time as determined by the Board.”
Akari Therapeutics Plc reported the first quarter ended March 31, 2024 results: net income Net loss was approximately $5.6 million.
“Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the first quarter ended March 31, 2024 as well as recent company highlights.”
Akari Therapeutics Plc announced a restructuring with charges of approximately $3.1 million to $3.2 million (approximately 67% of its total workforce).
“expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be in the range of approximately $3.1 million to $3.2 million, which includes approximately $1.6 million of non-cash expenses related to vesting of equity awards. The Company expects these costs to be payable through the”
Rachelle Jacques resigned as Director at Akari Therapeutics Plc.
“On May 7, 2024, Rachelle Jacques resigned from the Board of Directors (the “Board”), effective May 7, 2024.”
Samir R. Patel was appointed as Interim President and Chief Executive Officer at Akari Therapeutics Plc.
“the Board appointed Samir R. Patel, M.D., a member of the Board, to Interim President and Chief Executive Officer, effective May 1, 2024”
Melissa Bradford-Klug departed as Chief Operating Officer at Akari Therapeutics Plc.
“our Chief Operating Officer, Melissa Bradford-Klug, was terminated without cause, effective May 1, 2024.”
Rachelle Jacques departed as President and Chief Executive Officer at Akari Therapeutics Plc.
“Rachelle Jacques stepped down as the President and Chief Executive Officer of Akari Therapeutics, Plc (the “Company”), effective May 1, 2024.”
Akari Therapeutics Plc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 5, 2024, Akari Therapeutics, Plc (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”) is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity”
Akari Therapeutics Plc reported the full year ended December 31, 2023 results: net income Net loss was approximately $10.0 million for the year ended December 31, 2023.
“Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights”
Akari Therapeutics Plc entered into Purchase Agreement with certain existing investors valued at approximately $1,615,000 (effective 2024-03-11).
“On March 11, 2024, Akari Therapeutics, Plc (the “ Company ”) entered into a definitive agreement (the “ Purchase Agreement ”) with certain existing investors, pursuant to which the Company agreed to sell and issue in a private placement (the “ Private Placement ”) approximately $1,615,000 of unregistered American Depository Shares (“ ADSs ”)”
Akari Therapeutics Plc entered into Agreement and Plan of Merger with Peak Bio, Inc. (effective 2024-03-04).
“On March 4, 2024, Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (" Akari "), entered into an Agreement and Plan of Merger (the " Merger Agreement ") with Peak Bio, Inc. (" Peak Bio ") and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (" Merger Sub ")”
Akari Therapeutics Plc entered into Purchase Agreement with existing investors, the Company's Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D. valued at aggregate of 947,868 unregistered American Depository Shares ("ADSs"), each representing 2,000 of th (effective 2023-12-27).
“On December 27, 2023, Akari Therapeutics, Plc (the “Company”) entered into a definitive agreement (the “Purchase Agreement”) with existing investors, the Company’s Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., pursuant to which the Company agreed to sell and issue in a private placement (the “Private Placement”) an aggregate of 947,868 unregistered American Depository Shares (“ADSs”), each representing 2,000 of the Company’s ordinary shares, at a purchase price of $2.11 per ADS.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.